Literature DB >> 10716237

Reactive astrocytes express p53 in the spinal cord of transgenic mice expressing a human Cu/Zn SOD mutation.

K J Cho1, Y H Chung, C Shin, D H Shin, Y S Kim, M E Gurney, K W Lee, C I Cha.   

Abstract

In a previous study, we reported increased NOS expression in the astrocytes in the spinal cord of SOD mutant transgenic mice that are used as ALS animal model. Recently, Messmer and Brune suggested that nitric oxide-induced apoptosis is intimately related with p53-dependent signaling pathway, and de la Monte et al. reported increased p53-immunoreactivity in the spinal cord of ALS patients. In the present study, we performed immunocytochemical studies to investigate the changes of p53-immunoreactivity in the brains of the mutant transgenic mice expressing a human Cu/Zn SOD mutation. Immunocytochemistry showed intensely stained p53-IR glial cells with the appearance of astrocytes in all levels of the spinal cord of the mutant transgenic mice, but no p53-IR glial cells were observed in the spinal cord of the control mice. P53-IR astrocytes were also detected in the brain stem of the mutant transgenic mice. In the medulla, they were observed in the medullary reticular formation, hypoglossal nucleus, vestibular nucleus, dorsal motor nucleus of the vagus and nucleus ambiguus. In the pons, their presences were noted in the pontine reticular formation, and trigeminal and facial nuclei. In the midbrain, astrocytes were detected in the mesencephalic reticular formation, red nucleus and periaqueductal gray matter. In the cerebellum, intensely stained p53-IR astrocytes were detected in the intracerebellar nuclei. In contrast to the mutant transgenic mice, no p53-IR astrocytes were detected in the brain stem and spinal cord of the control mice. Further multidisciplinary investigations involving p53-mediated cellular damage and pathogenesis of ALS are needed to clarify the importance of these results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10716237     DOI: 10.1097/00001756-199912160-00039

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

1.  Reduction of circulating endothelial cells in peripheral blood of ALS patients.

Authors:  Svitlana Garbuzova-Davis; Robert L Woods; Michael K Louis; Theresa A Zesiewicz; Nicole Kuzmin-Nichols; Kelly L Sullivan; Amber M Miller; Diana G Hernandez-Ontiveros; Paul R Sanberg
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

2.  Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS.

Authors:  Svitlana Garbuzova-Davis; Maria C O Rodrigues; Santhia Mirtyl; Shanna Turner; Shazia Mitha; Jasmine Sodhi; Subatha Suthakaran; David J Eve; Cyndy D Sanberg; Nicole Kuzmin-Nichols; Paul R Sanberg
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

3.  Humoral factors in ALS patients during disease progression.

Authors:  Jared Ehrhart; Adam J Smith; Nicole Kuzmin-Nichols; Theresa A Zesiewicz; Israt Jahan; R Douglas Shytle; Seol-Hee Kim; Cyndy D Sanberg; Tuan H Vu; Clifton L Gooch; Paul R Sanberg; Svitlana Garbuzova-Davis
Journal:  J Neuroinflammation       Date:  2015-06-28       Impact factor: 8.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.